CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: POLR2J3 (ImmuneEditome ID:548644)

1. Gene summary of enriched editing regions for POLR2J3

check button Gene summary
Gene informationGene symbol

POLR2J3

Gene ID

548644

GeneSynonymsRPB11b2
GeneCytomap

7q22.1

GeneTypeprotein-coding
GeneDescriptionDNA-directed RNA polymerase II subunit RPB11-b2|DNA-directed RNA polymerase II subunit 11|DNA-directed RNA polymerase II subunit J3|RNA polymerase II subunit B11-b2|polymerase (RNA) II (DNA directed) polypeptide J3|polymerase (RNA) II subunit J3
GeneModificationdate20230329
UniprotIDE7EP90;A0A0B4J2F8;F8WF84;E7EWC6;A0A0B4J1Z8;E2QRJ6;D6RAG0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr7:102535756-102539214:-ENST00000379357.8ENSG00000168255.17POLR2J3exonicAluSx,FRAM,AluJr,(CTCCCC)n,AluSc,AluJb,MIRc,MIR3,L2cchr7:102535756-102539214:-.alignment
chr7:102544022-102545925:-ENST00000507355.4ENSG00000168255.17POLR2J3exonicAluSx,AluJb,MLT1A,AluSqchr7:102544022-102545925:-.alignment
chr7:102547915-102549222:-ENST00000502415.4ENSG00000168255.17POLR2J3ncRNA_intronic(T)n,AluSx,AluJochr7:102547915-102549222:-.alignment
chr7:102547915-102549222:-ENST00000503564.4ENSG00000168255.17POLR2J3ncRNA_intronic(T)n,AluSx,AluJochr7:102547915-102549222:-.alignment
chr7:102547915-102549222:-ENST00000504677.4ENSG00000168255.17POLR2J3ncRNA_intronic(T)n,AluSx,AluJochr7:102547915-102549222:-.alignment
chr7:102547915-102549222:-ENST00000506060.4ENSG00000168255.17POLR2J3ncRNA_intronic(T)n,AluSx,AluJochr7:102547915-102549222:-.alignment
chr7:102547915-102549222:-ENST00000511773.4ENSG00000168255.17POLR2J3ncRNA_intronic(T)n,AluSx,AluJochr7:102547915-102549222:-.alignment
chr7:102550371-102550673:-ENST00000502415.4ENSG00000168255.17POLR2J3ncRNA_intronicAluSx3,AluJrchr7:102550371-102550673:-.alignment
chr7:102550371-102550673:-ENST00000503564.4ENSG00000168255.17POLR2J3ncRNA_intronicAluSx3,AluJrchr7:102550371-102550673:-.alignment
chr7:102550371-102550673:-ENST00000504677.4ENSG00000168255.17POLR2J3ncRNA_intronicAluSx3,AluJrchr7:102550371-102550673:-.alignment
chr7:102550371-102550673:-ENST00000506060.4ENSG00000168255.17POLR2J3ncRNA_intronicAluSx3,AluJrchr7:102550371-102550673:-.alignment
chr7:102550371-102550673:-ENST00000511773.4ENSG00000168255.17POLR2J3ncRNA_intronicAluSx3,AluJrchr7:102550371-102550673:-.alignment
chr7:102565256-102566484:-ENST00000504157.4ENSG00000168255.17POLR2J3ncRNA_exonicAluSg7,Alu,AluSx,AluSq2chr7:102565256-102566484:-.alignment


Top

2. Tumor-specific enriched editing regions for POLR2J3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000168255.17,POLR2J3PRADEAG2.8269e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000168255.17,POLR2J3KIRPCliEAG3.9226e-043.4431e-040.3227image
ENSG00000168255.17,POLR2J3STADPathEAG1.3726e-021.1727e-02-0.1491image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr7:102544022-102545925:-BRCAEER8.6491e-031.8515e-023.0952e-02image
chr7:102535756-102539214:-UCSEER2.5940e-023.8626e-021.5823e+05image

Top

3. Enriched editing regions and immune related genes for POLR2J3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for POLR2J3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr7:102565256-102566484:-
ESCAEERIRENSG00000114737.11chr350608372:50608593:50611630:50611772-0.32522.9817e-024.9289e-05-0.4143imageNTAF15CISHT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr7:102547915-102549222:-
ESCAEERA5ENSG00000111011.13chr12122511110:122511188:122513766:122513869:122513768:122513869-0.25504.4876e-022.8020e-05-0.4177imageNIGF2BP2NA
chr7:102544022-102545925:-
ESCAEERIRENSG00000137496.13chr1171998908:71999662:71999926:71999938-0.32903.8440e-021.1588e-06-0.4269imageNIGF2BP2IL18BPMacrophages_M1GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
ENSG00000168255.17,POLR2J3
LUSCEAGIRENSG00000168255.14chr7102543524:102543661:102544705:1025447760.44411.4344e-142.1253e-170.4219imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;METTL3;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000168255.17,POLR2J3
TGCTEAGA3ENSG00000130313.2chr1917516172:17516280:17516370:17516474:17516367:175164740.25502.2603e-025.3516e-050.4022imageNADAR;AIFM1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_gamma_deltaGSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000168255.17,POLR2J3
TGCTEAGMEXENSG00000129657.10chr1777215779:77215792:77215831:77215909:77215909:77215935:77216023:772160360.27561.1994e-022.2487e-050.4046imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;METTL3;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000168255.17,POLR2J3
TGCTEAGIRENSG00000182179.6chr349809977:49810428:49810516:49810532-0.33211.5091e-022.1282e-05-0.4038imageNAUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;LIN28;LIN28B;LSM11;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;XRN2;ZNF184NAT_cells_gamma_deltaGSVA_HALLMARK_GLYCOLYSIS
ENSG00000168255.17,POLR2J3
THYMEAGIRENSG00000118418.10chr679201244:79202155:79202275:792023850.41432.1369e-022.9338e-050.4465imageNACIN1;ADAR;BUD13;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FTO;FUS;FXR2;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LIN28B;MBNL2;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184NANK_cells_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
ENSG00000168255.17,POLR2J3
THYMEAGESENSG00000066117.10chr1250099486:50099565:50099796:50099900:50100053:50100318-0.34922.9850e-021.2997e-04-0.4149imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NA
ENSG00000168255.17,POLR2J3
THYMEAGA3ENSG00000186818.8chr1954666696:54666749:54667637:54667699:54667634:54667699-0.38923.1041e-023.5223e-05-0.4557imageNADAR;DGCR8;EIF4A3;FUS;HNRNPL;NOP56;TAF15;UPF1LILRB4GSVA_HALLMARK_ANDROGEN_RESPONSE

More results



Top

5. Enriched editing regions and immune infiltration for POLR2J3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000168255.17,POLR2J3ACCEAGMacrophages_M06.2476e-03-0.5040image
chr7:102544022-102545925:-BLCAEERMacrophages_M03.6342e-020.1500image
chr7:102544022-102545925:-BRCAEERMast_cells_activated1.7114e-020.0936image
ENSG00000168255.17,POLR2J3BRCAEAGNK_cells_activated2.3484e-03-0.1098image
ENSG00000168255.17,POLR2J3CESCEAGDendritic_cells_activated2.3972e-020.1482image
chr7:102535756-102539214:-CHOLEERNK_cells_resting5.8280e-040.6869image
chr7:102544022-102545925:-CHOLEERDendritic_cells_activated9.6987e-030.4573image
ENSG00000168255.17,POLR2J3CHOLEAGDendritic_cells_activated1.4736e-030.5239image
ENSG00000168255.17,POLR2J3COADEAGEosinophils3.9793e-020.1896image
chr7:102535756-102539214:-ESCAEERMacrophages_M01.0268e-02-0.2708image
chr7:102544022-102545925:-ESCAEERMacrophages_M11.6181e-020.2090image
chr7:102547915-102549222:-ESCAEERMonocytes4.6551e-02-0.1806image
chr7:102550371-102550673:-ESCAEERMacrophages_M13.0660e-020.3380image
chr7:102535756-102539214:-GBMEERMonocytes2.2571e-020.2564image
chr7:102544022-102545925:-GBMEERB_cells_naive5.2815e-03-0.2654image
ENSG00000168255.17,POLR2J3GBMEAGPlasma_cells1.6814e-02-0.2188image
ENSG00000168255.17,POLR2J3HNSCEAGPlasma_cells1.3098e-02-0.1514image
chr7:102544022-102545925:-KIRCEERT_cells_gamma_delta1.1284e-020.1811image
ENSG00000168255.17,POLR2J3KIRCEAGDendritic_cells_activated1.3593e-020.1604image
ENSG00000168255.17,POLR2J3KIRPEAGT_cells_CD4_memory_activated3.1765e-040.2661image
chr7:102565256-102566484:-LAMLEERMacrophages_M27.6449e-03-0.3098image
ENSG00000168255.17,POLR2J3LGGEAGT_cells_regulatory_(Tregs)5.9125e-03-0.1412image
chr7:102535756-102539214:-LIHCEERMast_cells_resting1.6963e-020.2584image
ENSG00000168255.17,POLR2J3LIHCEAGDendritic_cells_activated1.2394e-040.3134image
ENSG00000168255.17,POLR2J3LUADEAGMacrophages_M12.6283e-020.1258image
chr7:102535756-102539214:-LUSCEERMast_cells_activated3.0539e-03-0.1997image
chr7:102544022-102545925:-LUSCEERMacrophages_M21.3139e-020.1440image
ENSG00000168255.17,POLR2J3LUSCEAGT_cells_CD81.6189e-020.1249image
chr7:102544022-102545925:-OVEERT_cells_CD4_naive3.1708e-030.2119image
chr7:102565256-102566484:-OVEERT_cells_CD4_memory_activated6.5791e-030.2263image
ENSG00000168255.17,POLR2J3PAADEAGPlasma_cells1.2621e-02-0.2462image
chr7:102535756-102539214:-PCPGEERB_cells_naive1.9254e-020.2875image
ENSG00000168255.17,POLR2J3PCPGEAGDendritic_cells_resting1.1025e-02-0.2460image
ENSG00000168255.17,POLR2J3PRADEAGPlasma_cells3.9596e-02-0.1376image
ENSG00000168255.17,POLR2J3SARCEAGMacrophages_M08.0233e-03-0.2390image
chr7:102544022-102545925:-STADEERT_cells_CD85.0461e-040.2266image
chr7:102547915-102549222:-STADEERMacrophages_M02.9871e-020.1647image
chr7:102565256-102566484:-STADEERT_cells_CD4_memory_activated3.4930e-020.1439image
ENSG00000168255.17,POLR2J3STADEAGT_cells_CD85.4447e-030.1601image
chr7:102535756-102539214:-THCAEERNK_cells_resting4.5081e-020.1042image
ENSG00000168255.17,POLR2J3THCAEAGT_cells_gamma_delta6.0553e-030.1363image
chr7:102544022-102545925:-THYMEERMacrophages_M11.1705e-020.3208image
ENSG00000168255.17,POLR2J3UCECEAGDendritic_cells_resting8.0532e-03-0.2585image


Top

6. Enriched editing regions and immune gene sets for POLR2J3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
ENSG00000168255.17,POLR2J3THCAEAG1.7025e-03image3.8232e-02-0.1031image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000168255.17,POLR2J3ACCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.4587e-020.4566image
ENSG00000168255.17,POLR2J3BLCAGSVA_HALLMARK_SPERMATOGENESISEAG2.4574e-020.1334image
chr7:102544022-102545925:-BLCAGSVA_HALLMARK_UV_RESPONSE_UPEER1.0594e-050.3096image
ENSG00000168255.17,POLR2J3BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG3.8892e-120.2473image
chr7:102544022-102545925:-BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER2.1840e-090.2323image
ENSG00000168255.17,POLR2J3CESCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.2240e-030.2110image
chr7:102544022-102545925:-CHOLGSVA_HALLMARK_HEME_METABOLISMEER8.1953e-030.4663image
ENSG00000168255.17,POLR2J3COADGSVA_HALLMARK_ADIPOGENESISEAG2.1100e-02-0.2121image
chr7:102544022-102545925:-ESCAGSVA_HALLMARK_APOPTOSISEER5.8871e-050.3423image
chr7:102565256-102566484:-ESCAGSVA_HALLMARK_HYPOXIAEER7.8542e-030.2406image
chr7:102535756-102539214:-ESCAGSVA_HALLMARK_P53_PATHWAYEER1.1537e-02-0.2667image
ENSG00000168255.17,POLR2J3ESCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.1303e-020.2036image
chr7:102544022-102545925:-GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.0749e-020.2434image
ENSG00000168255.17,POLR2J3GBMGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.9665e-020.1994image
chr7:102535756-102539214:-GBMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER7.7166e-030.2977image
ENSG00000168255.17,POLR2J3HNSCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG7.6716e-04-0.2043image
ENSG00000168255.17,POLR2J3KICHGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.7211e-020.3715image
ENSG00000168255.17,POLR2J3KIRCGSVA_HALLMARK_HYPOXIAEAG3.3036e-030.1905image
chr7:102544022-102545925:-KIRCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER4.3296e-060.3223image
ENSG00000168255.17,POLR2J3KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.4650e-040.2801image
ENSG00000168255.17,POLR2J3LAMLGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG6.3882e-040.2861image
ENSG00000168255.17,POLR2J3LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG1.0156e-040.1983image
chr7:102535756-102539214:-LIHCGSVA_HALLMARK_HEME_METABOLISMEER1.3521e-020.2670image
ENSG00000168255.17,POLR2J3LIHCGSVA_HALLMARK_HEME_METABOLISMEAG8.4759e-040.2742image
ENSG00000168255.17,POLR2J3LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.4717e-040.1946image
chr7:102544022-102545925:-LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.0675e-050.2326image
chr7:102547915-102549222:-LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.3043e-02-0.4215image
chr7:102544022-102545925:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.3293e-030.1763image
chr7:102535756-102539214:-LUSCGSVA_HALLMARK_P53_PATHWAYEER8.8506e-03-0.1769image
ENSG00000168255.17,POLR2J3LUSCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.7521e-05-0.2212image
ENSG00000168255.17,POLR2J3MESOGSVA_HALLMARK_KRAS_SIGNALING_UPEAG7.9553e-030.3866image
chr7:102544022-102545925:-OVGSVA_HALLMARK_MITOTIC_SPINDLEEER2.2975e-04-0.2629image
chr7:102547915-102549222:-OVGSVA_HALLMARK_COAGULATIONEER3.5414e-040.2998image
chr7:102565256-102566484:-OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER5.6039e-090.4634image
ENSG00000168255.17,POLR2J3OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG4.7702e-030.1755image
chr7:102544022-102545925:-PAADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER4.8137e-020.2176image
ENSG00000168255.17,POLR2J3PCPGGSVA_HALLMARK_MYC_TARGETS_V2EAG2.4543e-02-0.2183image
chr7:102535756-102539214:-PCPGGSVA_HALLMARK_DNA_REPAIREER8.5043e-03-0.3214image
ENSG00000168255.17,POLR2J3PRADGSVA_HALLMARK_PEROXISOMEEAG1.7693e-03-0.2078image
ENSG00000168255.17,POLR2J3READGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.8275e-020.3346image
ENSG00000168255.17,POLR2J3SARCGSVA_HALLMARK_KRAS_SIGNALING_UPEAG9.1011e-03-0.2352image
chr7:102544022-102545925:-SKCMGSVA_HALLMARK_COMPLEMENTEER3.7707e-030.2000image
ENSG00000168255.17,POLR2J3SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.5639e-040.2288image
chr7:102565256-102566484:-STADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.3650e-050.2788image
chr7:102547915-102549222:-STADGSVA_HALLMARK_GLYCOLYSISEER8.8489e-060.3298image
chr7:102535756-102539214:-STADGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.2295e-02-0.2311image
chr7:102544022-102545925:-STADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER7.3770e-040.2201image
ENSG00000168255.17,POLR2J3STADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.6153e-030.1813image
ENSG00000168255.17,POLR2J3TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEAG5.5868e-030.2580image
chr7:102535756-102539214:-THCAGSVA_HALLMARK_SPERMATOGENESISEER2.0612e-020.1203image
ENSG00000168255.17,POLR2J3THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.3898e-06-0.2322image
ENSG00000168255.17,POLR2J3THYMGSVA_HALLMARK_NOTCH_SIGNALINGEAG9.2361e-030.2824image
chr7:102544022-102545925:-THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.2293e-02-0.3187image
ENSG00000168255.17,POLR2J3UCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.2031e-030.2579image
ENSG00000168255.17,POLR2J3UCSGSVA_HALLMARK_SPERMATOGENESISEAG1.3049e-020.4155image


Top

7. Enriched editing regions and drugs for POLR2J3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000168255.17,POLR2J3ACCGSK269962AEAG2.3695e-030.5511image
chr7:102535756-102539214:-BLCALenalidomideEER1.0509e-02-0.1806image
chr7:102544022-102545925:-BLCAABT.888EER3.5484e-030.2078image
ENSG00000168255.17,POLR2J3BLCAErlotinibEAG4.5038e-040.2069image
chr7:102544022-102545925:-BRCAABT.263EER1.0007e-040.1525image
ENSG00000168255.17,POLR2J3BRCAGW843682XEAG7.2596e-110.2326image
ENSG00000168255.17,POLR2J3CESCBosutinibEAG4.6842e-060.2954image
ENSG00000168255.17,POLR2J3CHOLElesclomolEAG2.8269e-020.3763image
chr7:102535756-102539214:-CHOLDoxorubicinEER4.8668e-030.5901image
chr7:102544022-102545925:-CHOLBMS.536924EER2.8461e-030.5179image
ENSG00000168255.17,POLR2J3COADAZ628EAG1.3082e-020.2279image
ENSG00000168255.17,POLR2J3DLBCBMS.708163EAG1.7268e-02-0.5021image
chr7:102565256-102566484:-ESCAAZD8055EER3.7629e-03-0.2615image
ENSG00000168255.17,POLR2J3ESCAABT.263EAG4.2740e-020.1640image
chr7:102547915-102549222:-ESCAABT.263EER2.3619e-020.2048image
chr7:102535756-102539214:-ESCAA.770041EER5.6243e-03-0.2912image
chr7:102550371-102550673:-ESCAAMG.706EER1.6437e-02-0.3726image
chr7:102544022-102545925:-ESCAABT.263EER8.0168e-040.2883image
chr7:102544022-102545925:-GBMBosutinibEER6.6796e-030.2584image
ENSG00000168255.17,POLR2J3GBMBMS.536924EAG1.8039e-030.2832image
chr7:102535756-102539214:-GBMAP.24534EER2.5007e-02-0.2521image
ENSG00000168255.17,POLR2J3HNSCErlotinibEAG2.1454e-030.1874image
ENSG00000168255.17,POLR2J3KICHATRAEAG3.3747e-020.3954image
ENSG00000168255.17,POLR2J3KIRCBMS.708163EAG5.6645e-04-0.2228image
chr7:102544022-102545925:-KIRCBMS.708163EER2.7393e-04-0.2578image
ENSG00000168255.17,POLR2J3KIRPGSK.650394EAG2.4034e-040.2712image
chr7:102565256-102566484:-LAMLEHT.1864EER4.2306e-020.2383image
ENSG00000168255.17,POLR2J3LAMLGDC0941EAG6.0438e-040.2873image
chr7:102547915-102549222:-LAMLErlotinibEER8.7186e-030.2560image
ENSG00000168255.17,POLR2J3LGGGW843682XEAG6.9019e-050.2030image
chr7:102535756-102539214:-LIHCATRAEER1.1468e-03-0.3529image
ENSG00000168255.17,POLR2J3LIHCATRAEAG2.5573e-06-0.3829image
chr7:102544022-102545925:-LUADBleomycinEER1.1588e-02-0.1512image
chr7:102535756-102539214:-LUSCLapatinibEER1.9778e-040.2495image
ENSG00000168255.17,POLR2J3LUSCAZD8055EAG5.7246e-05-0.2076image
chr7:102547915-102549222:-LUSCCI.1040EER1.2531e-030.5304image
chr7:102544022-102545925:-LUSCAZ628EER1.1473e-03-0.1881image
ENSG00000168255.17,POLR2J3MESOMidostaurinEAG4.1695e-03-0.4146image
chr7:102544022-102545925:-OVGDC.0449EER3.7636e-04-0.2541image
ENSG00000168255.17,POLR2J3OVBexaroteneEAG2.1086e-030.1909image
chr7:102547915-102549222:-OVAS601245EER1.9165e-03-0.2619image
chr7:102565256-102566484:-OVBMS.536924EER6.5832e-05-0.3274image
chr7:102544022-102545925:-PAADCI.1040EER1.6595e-020.2623image
ENSG00000168255.17,POLR2J3PAADJNK.Inhibitor.VIIIEAG4.2305e-03-0.2810image
chr7:102535756-102539214:-PCPGAZD6482EER9.6676e-03-0.3163image
ENSG00000168255.17,POLR2J3PCPGAZD6482EAG1.7841e-02-0.2297image
ENSG00000168255.17,POLR2J3PRADDocetaxelEAG1.3067e-020.1660image
ENSG00000168255.17,POLR2J3READDocetaxelEAG1.5008e-020.3686image
ENSG00000168255.17,POLR2J3SARCCEP.701EAG8.6467e-040.2978image
chr7:102544022-102545925:-SKCMEmbelinEER5.5247e-03-0.1918image
ENSG00000168255.17,POLR2J3SKCMEmbelinEAG1.8806e-04-0.2336image
ENSG00000168255.17,POLR2J3STADBMS.509744EAG2.9880e-03-0.1709image
chr7:102565256-102566484:-STADCI.1040EER5.9447e-04-0.2323image
chr7:102544022-102545925:-STADBMS.509744EER5.9255e-03-0.1802image
chr7:102535756-102539214:-STADBMS.509744EER4.3960e-03-0.3043image
chr7:102547915-102549222:-STADIPA.3EER4.9541e-020.1491image
ENSG00000168255.17,POLR2J3TGCTFH535EAG4.6020e-02-0.1873image
chr7:102535756-102539214:-THCABleomycinEER2.3976e-030.1574image
ENSG00000168255.17,POLR2J3THCAErlotinibEAG7.8543e-060.2203image
chr7:102544022-102545925:-THYMCGP.082996EER1.2417e-020.3183image
ENSG00000168255.17,POLR2J3THYMCMKEAG3.6783e-030.3136image
ENSG00000168255.17,POLR2J3UCECJNK.Inhibitor.VIIIEAG7.5299e-05-0.3782image
ENSG00000168255.17,POLR2J3UCSEmbelinEAG4.0706e-02-0.3477image
chr7:102535756-102539214:-UCSFH535EER2.6577e-02-0.4344image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType